These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34922644)

  • 1. Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia.
    Lewis GF; Hegele RA
    Lancet Diabetes Endocrinol; 2022 Feb; 10(2):142-148. PubMed ID: 34922644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demystifying the management of hypertriglyceridaemia.
    Watts GF; Ooi EM; Chan DC
    Nat Rev Cardiol; 2013 Nov; 10(11):648-61. PubMed ID: 24060958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
    Picard F; Steg PG
    Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
    Hernandez P; Passi N; Modarressi T; Kulkarni V; Soni M; Burke F; Bajaj A; Soffer D
    Curr Atheroscler Rep; 2021 Sep; 23(11):72. PubMed ID: 34515873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society].
    Pedro-Botet J; Barrios V; Sánchez-Margalet V; Tamargo J; Arrieta F; Gámez JM; Gimeno-Orna JA; Escobar C; Gómez-Doblas JJ; Pérez A;
    Endocrinol Diabetes Nutr (Engl Ed); 2023 Mar; 70 Suppl 1():51-62. PubMed ID: 36402735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential options to treat hypertriglyceridaemia.
    Viljoen A; Wierzbicki AS
    Curr Drug Targets; 2009 Apr; 10(4):356-62. PubMed ID: 19355860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N; Miller M
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertriglyceridemia.
    Chait A
    Endocrinol Metab Clin North Am; 2022 Sep; 51(3):539-555. PubMed ID: 35963627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
    Shepherd J; Betteridge J; Van Gaal L;
    Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertriglyceridaemia: contemporary management of a neglected cardiovascular risk factor.
    Khan TZ; Schatz U; Bornstein SR; Barbir M
    Glob Cardiol Sci Pract; 2021 Oct; 2021(3):e202119. PubMed ID: 34805377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of dyslipidemia in the metabolic syndrome.
    Tan KC
    Cardiovasc Hematol Disord Drug Targets; 2007 Jun; 7(2):99-108. PubMed ID: 17584044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is hypertriglyceridaemia a risk factor for coronary heart disease?].
    Reiner Z; Muacević-Katanec D; Katanec D; Tedeschi-Reiner E
    Lijec Vjesn; 2012; 134(3-4):105-11. PubMed ID: 22768685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triglycerides and residual risk.
    Vallejo-Vaz AJ; Corral P; Schreier L; Ray KK
    Curr Opin Endocrinol Diabetes Obes; 2020 Apr; 27(2):95-103. PubMed ID: 32073428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review.
    Kolovou GD; Watts GF; Mikhailidis DP; Pérez-Martínez P; Mora S; Bilianou H; Panotopoulos G; Katsiki N; Ooi TC; Lopez-Miranda J; Tybjærg-Hansen A; Tentolouris N; Nordestgaard BG
    Curr Vasc Pharmacol; 2019; 17(5):515-537. PubMed ID: 31309820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text.
    Kolovou GD; Watts GF; Mikhailidis DP; Pérez-Martínez P; Mora S; Bilianou H; Panotopoulos G; Katsiki N; Ooi TC; Lopez-Miranda J; Tybjærg-Hansen A; Tentolouris N; Nordestgaard BG
    Curr Vasc Pharmacol; 2019; 17(5):498-514. PubMed ID: 31060488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of mild-to-moderate hypertriglyceridemia.
    Pérez-Martínez P; Pérez-Jiménez F
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():69-74. PubMed ID: 34006357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment for patients with the metabolic syndrome.
    Ginsberg HN
    Am J Cardiol; 2003 Apr; 91(7A):29E-39E. PubMed ID: 12679201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.